JP2010533478A5 - - Google Patents

Download PDF

Info

Publication number
JP2010533478A5
JP2010533478A5 JP2010516305A JP2010516305A JP2010533478A5 JP 2010533478 A5 JP2010533478 A5 JP 2010533478A5 JP 2010516305 A JP2010516305 A JP 2010516305A JP 2010516305 A JP2010516305 A JP 2010516305A JP 2010533478 A5 JP2010533478 A5 JP 2010533478A5
Authority
JP
Japan
Prior art keywords
gamma secretase
seq
ledaefrhds
lvml
substrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010516305A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010533478A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from US12/172,978 external-priority patent/US20090023158A1/en
Publication of JP2010533478A publication Critical patent/JP2010533478A/ja
Publication of JP2010533478A5 publication Critical patent/JP2010533478A5/ja
Withdrawn legal-status Critical Current

Links

JP2010516305A 2007-07-13 2008-07-14 ガンマセクレターゼの阻害剤の基質特異性を同定するための組成物および方法 Withdrawn JP2010533478A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94973807P 2007-07-13 2007-07-13
US12/172,978 US20090023158A1 (en) 2007-07-13 2008-07-14 Compositions and Methods for Identifying Substrate Specificity of Inhibitors of Gamma Secretase
PCT/US2008/070012 WO2009012237A1 (en) 2007-07-13 2008-07-14 Compositions and methods for identifying substrate specificity of inhibitors of gamma secretase

Publications (2)

Publication Number Publication Date
JP2010533478A JP2010533478A (ja) 2010-10-28
JP2010533478A5 true JP2010533478A5 (enExample) 2011-09-01

Family

ID=39739883

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010516305A Withdrawn JP2010533478A (ja) 2007-07-13 2008-07-14 ガンマセクレターゼの阻害剤の基質特異性を同定するための組成物および方法

Country Status (5)

Country Link
US (2) US20090023158A1 (enExample)
EP (1) EP2183598A1 (enExample)
JP (1) JP2010533478A (enExample)
CA (1) CA2692604A1 (enExample)
WO (1) WO2009012237A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2166110B1 (en) * 2007-06-08 2012-02-22 Eisai R&D Management Co., Ltd. Screening method utilizing novel substrate epha4 for gamma-secretase
EP2177623A4 (en) * 2007-07-19 2010-12-29 Eisai R&D Man Co Ltd SCREENING METHOD USING C-MET, A NEW SUBSTRATE FOR GAMMA SECRETASE
WO2009017234A1 (ja) * 2007-08-01 2009-02-05 Eisai R & D Management Co., Ltd. γ-セクレターゼの新規基質c-Retを利用したスクリーニング方法
US20090163594A1 (en) * 2007-10-31 2009-06-25 Elan Pharmaceuticals, Inc. Triple Assay System for Identifying Substrate Selectivity of Gamma Secretase Inhibitors
US8530181B2 (en) * 2007-11-15 2013-09-10 Eisai R&D Management Co., Ltd. Method of screening for compounds which affect the cleavage of EphA7 byγ-secretase
US7892769B2 (en) * 2007-11-30 2011-02-22 Eisai R&D Management Co., Ltd. Processing of EphA4 polypeptide by γ-secretase activity
WO2012081502A1 (ja) 2010-12-17 2012-06-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 ゼラチナーゼによるEphA4の切断反応を指標としたスクリーニング方法
US9784751B2 (en) 2011-04-25 2017-10-10 Eisai R&D Management Co., Ltd. Method for detecting neurological disease associated with cognitive impairment by measuring EphA4 extracellular domain
KR102038357B1 (ko) 2012-06-22 2019-10-31 젠티엄 에스알엘 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법
EP3026122A1 (en) * 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
WO2019169243A1 (en) * 2018-03-02 2019-09-06 Ionis Pharmaceuticals, Inc. Compounds and methods for the modulation of amyloid-beta precursor protein
EP3995582B1 (en) 2019-07-01 2026-04-22 Eisai R&D Management Co., Ltd. Anti-epha4 antibody
US11913964B2 (en) 2020-02-27 2024-02-27 Adeptrix Corp. Multiplexed bead-based analytical assays
WO2021206910A1 (en) * 2020-04-09 2021-10-14 The Regents Of The University Of California Notch receptors with zinc finger-containing transcriptional effector
MX2023001222A (es) 2020-07-28 2023-04-26 Ionis Pharmaceuticals Inc Compuestos y metodos para reducir la expresion de app.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441870A (en) 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5604102A (en) * 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5605811A (en) * 1992-10-26 1997-02-25 Athena Neurosciences, Inc. Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
AU702293B2 (en) * 1993-10-27 1999-02-18 Athena Neurosciences, Inc. Transgenic animals harboring APP allele having Swedish mutation
DE10131899A1 (de) * 2001-07-04 2003-02-27 Boehringer Ingelheim Pharma In vitro-Screening-Assay für gamma-Secretase
WO2007058987A1 (en) * 2005-11-10 2007-05-24 Bristol-Myers Squibb Company Methods of identifying compounds that inhibit notch cleavage
US20090163594A1 (en) * 2007-10-31 2009-06-25 Elan Pharmaceuticals, Inc. Triple Assay System for Identifying Substrate Selectivity of Gamma Secretase Inhibitors

Similar Documents

Publication Publication Date Title
CY1108689T1 (el) Ολιγοπεπτιδια για την ελαττωση αυξημενης συγκεντρωσεως της ουριας στο αιμα
JP2010510315A5 (enExample)
JP2013539454A5 (enExample)
WO2007148224A3 (en) Polypeptide
MX2011011130A (es) Proteina o peptido de fusion con vida media in vivo incrementada mantenido por liberacion in vivo sostenida, y metodo para incrementar la vida media in vivo usando el mismo.
JP2008536483A5 (enExample)
EP1801206A4 (en) PROCESS FOR THE PREPARATION OF L-ARGININE, L-ORNITHIN OR L-CITRULLINE
WO2009024327A3 (en) New proteins for use in human and animal staphylococcus infections
NO20092567L (no) Acetylendenvater og deres anvendelse til binding og avbilding av amyloidplakker
JP2021505620A5 (enExample)
JP2009505964A5 (enExample)
WO2009079212A3 (en) Linked peptide fluorogenic biosensors
JP2016513471A5 (enExample)
WO2005119251A3 (en) Novel means and methods for the treatment of hearing loss and phantom hearing
JP2009527503A5 (enExample)
WO2009107971A3 (ko) 포스파티딜세린과 특이적으로 결합하는 폴리펩티드 및 이의 용도
JP2010512326A5 (enExample)
JP2005512547A5 (enExample)
ATE488252T1 (de) Erhöhte transduktion mit abc- transportersubstratenhemmern
WO2008142664A3 (en) Exposed thymidine kinase 1 peptides, ligands and methods employing the same
JP2014534173A5 (enExample)
JP2009067947A5 (enExample)
Heidmeier et al. A single amino acid substitution in the measles virus F2 protein reciprocally modulates membrane fusion activity in pathogenic and oncolytic strains
WO2009105780A3 (en) Mntf peptide compositions and methods of use
JP2010053172A5 (enExample)